Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1318P (RNA, U6 small nuclear 1318, pseudogene) is classified as a pseudogene of the U6 small nuclear RNA (snRNA) gene family[1]. Pseudogenes are genomic sequences similar to normal genes but are non-functional, often resulting from gene duplication or retrotransposition processes. Unlike functional U6 snRNA, which plays a critical role in the spliceosome as part of pre-mRNA splicing[2][4], pseudogenes like RNU6-1318P do not encode functional RNA products and have no known biological function or involvement in disease mechanisms[1][3]. There is no evidence that RNU6-1318P is a therapeutic target or has drug interactions. Pseudogenes can sometimes serve as markers of retrotransposition activity in the genome but are not considered active molecular targets for therapy or drug discovery[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1318, pseudogene (RNU6-1318P).